Filing Flows › Neuroone Medical Technologies (NMTC) › Who owns the stock
Who owns Neuroone Medical Technologies (NMTC) stock
24 funds reported Neuroone Medical Technologies (NMTC) shares in their latest 13F filings, worth $5.5M in all. The largest holder is Bleichroeder LP ($2.0M). Last quarter 23 funds added to their stakes and 1 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Bleichroeder LP | 666,666 | $2.0M | new | 2026-06-30 |
| Vanguard Capital Management LLC | 352,774 | $1.1M | new | 2026-06-30 |
| Bard Associates | 305,428 | $929K | new | 2026-06-30 |
| Geode Capital Management, LLC | 93,555 | $284K | new | 2026-06-30 |
| Sio Capital Management, LLC | 82,767 | $252K | new | 2026-06-30 |
| Renaissance Technologies LLC | 70,861 | $215K | new | 2026-06-30 |
| Perkins Capital Management | 159,854 | $165K | decrease | 2026-09-30 |
| Vanguard Fiduciary Trust | 49,018 | $149K | new | 2026-06-30 |
| BlackRock | 25,121 | $76K | new | 2026-06-30 |
| Northern Trust | 21,398 | $65K | new | 2026-06-30 |
| Citadel Advisors LLC | 15,032 | $46K | new | 2026-06-30 |
| Susquehanna International Group, LLP | 13,520 | $41K | new | 2026-06-30 |
| Belpointe Asset Management LLC | 12,500 | $38K | new | 2026-06-30 |
| Legato Capital Management LLC | 10,273 | $31K | new | 2026-06-30 |
| Cambridge Investment Research Advisors | 28,715 | $30K | increase | 2026-09-30 |
Neuroone Medical Technologies' latest quarter
Neuroone Medical Technologies, Q3 FY26: revenue $2.0M (+16% year over year), operating margin -122.9%, net loss $2.0M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most NMTC stock?
By the latest 13F filings: Bleichroeder LP ($2.0M); Vanguard Capital Management LLC ($1.1M); Bard Associates ($929K); Geode Capital Management, LLC ($284K); Sio Capital Management, LLC ($252K).
What is the short interest in NMTC?
207,315 shares were sold short at the 2026-10-15 settlement, 15.99% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.